Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.
about
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic StrategiesImmunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusionInterleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosisMicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ production.Current and future approaches for control of graft-versus-host disease.Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.The biology of graft-versus-host disease: experimental systems instructing clinical practice.Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cellsThe role of interleukin-12 and interferon-gamma in GVHD and GVL.Advances in graft-versus-host disease biology and therapy.Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems.Effects of small intestinal submucosa (SIS) on the murine innate immune microenvironment induced by heat-killed Staphylococcus aureus.Decreased levels of circulating IL17-producing CD161+CCR6+ T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation.Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.Altered effector CD4+ T cell function in IL-21R-/- CD4+ T cell-mediated graft-versus-host diseaseSequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.HDAC inhibition and graft versus host diseaseImmune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation.The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigmaHost basophils are dispensable for induction of donor T helper 2 cell differentiation and severity of experimental graft-versus-host disease.The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantationAbsence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation.Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanismPrevention of graft-versus-host disease by anti IL-7Ralpha antibody.Pathophysiology of acute graft-versus-host disease: recent advances.STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewPreemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activityExpression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.Allogeneic Th1 cells home to host bone marrow and spleen and mediate IFNγ-dependent aplasia.Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease.IL-17 contributes to CD4-mediated graft-versus-host disease.In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestationsHost-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease.Biology of chronic graft-versus-host disease: implications for a future therapeutic approach.
P2860
Q26751959-2354FF13-38BB-4777-8DCC-BF8D60DDFDAAQ28296706-E3B5C995-183F-45E5-ABF2-291B3728EED5Q28591879-3F7E092F-1EF3-42AB-9311-4923D8FE2FB6Q30278940-9B88B5C1-0575-4DD3-8C71-543F0BDF87F0Q33642625-AB899BF8-AFD8-43D2-9F6B-4431DBDBAEF0Q33774610-71DBC153-11DF-4F75-B13F-562B4D92B00CQ33917175-551061F7-6DA0-432E-AA47-E3E8C40CD9ABQ33931876-C6F017E9-A0F2-47FF-8774-49C5D246C60FQ34025160-C4400EF9-A929-4F5A-BBC5-E0417F18F840Q34031916-1635FBDB-DEE4-4FF1-8235-EDE9CFE1B372Q34143148-043CE3BA-D768-4977-9D3F-27D764A1BAE7Q34493710-16573183-0CAF-43EA-B0E7-D903C3873F3AQ34506636-8451E90A-63E1-403E-8FE6-F84DC054E92FQ34640239-5579BFD3-9C2F-405A-9CDC-3F207EFC6AAEQ34643444-0AC33736-FBA8-4B31-9E19-CC04CCE8AD8DQ34703720-C3B56C37-E366-43E8-8BFF-2C527BA7B92DQ34754302-38F3B138-695E-4517-8BBC-4A4D41EB79A2Q35016985-23AD6BEF-8E8D-4EEC-8AB6-242643F47BF7Q35080319-C786759C-F187-4C07-A3BE-FF499A6C2BCFQ35084404-1E131A86-E131-446B-A644-51A57C5F20A7Q35563471-B78E4596-D136-41E7-AA50-57E5E8EEB362Q35607302-8091728C-9DC3-49DC-8916-7C6485AFC8D8Q35669245-A4463179-9C38-43CF-9487-0F73F4E0CDFCQ35804518-6203D812-1C5B-4198-B39B-A0071362B1D9Q35848468-13409E49-713F-49FF-A7FB-9C785F77A675Q35866143-40FC9BCA-9032-441B-88F8-0103FFCAA776Q36059590-D27936E7-B8CA-4F5E-9351-D754E065C2C6Q36156559-D8F50A9E-7AAF-412A-85E0-34E2029CFB07Q36231545-19121603-0F12-4F4E-A420-A04F4091A3ACQ36408216-97957644-3F3F-440C-ADD5-C1956D91C6D9Q36447926-6E7D8ED9-D2B6-4708-B304-1D1347A950F8Q36761824-D6B8A49B-6911-479B-9D6A-42E07B639443Q36843812-5AF8885A-E3A2-44FA-914C-D8EA50FDAC5DQ36931745-47FC9494-A120-41D7-9D2C-679AD0B512E2Q37002030-AC1504AE-1422-48FD-9428-9A406B311103Q37016873-36D1EB7D-C571-48A5-B65A-971D3084A150Q37071147-317C02AC-E635-4559-B103-16BEC1116E64Q37086953-0E8E346B-C182-4271-B244-6F15E118F12AQ37236537-D38EF599-FE67-4847-8C92-E7D9B776F4EBQ37294468-1D90F87D-56AC-4105-9E88-E59383B9D622
P2860
Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Th1 and Th2 mediate acute graf ...... th distinct end-organ targets.
@ast
Th1 and Th2 mediate acute graf ...... th distinct end-organ targets.
@en
type
label
Th1 and Th2 mediate acute graf ...... th distinct end-organ targets.
@ast
Th1 and Th2 mediate acute graf ...... th distinct end-organ targets.
@en
prefLabel
Th1 and Th2 mediate acute graf ...... th distinct end-organ targets.
@ast
Th1 and Th2 mediate acute graf ...... th distinct end-organ targets.
@en
P2093
P2860
P356
P1476
Th1 and Th2 mediate acute graf ...... th distinct end-organ targets.
@en
P2093
P2860
P304
P356
10.1172/JCI7894
P407
P577
2000-05-01T00:00:00Z